Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
acquired by Amgen
|
| gptkbp:ceo |
gptkb:Dr._R._Scott_Greer
|
| gptkbp:focus |
therapeutics
|
| gptkbp:founded |
gptkb:2016
gptkb:2021 |
| gptkbp:founder |
gptkb:Teneobio,_Inc.
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teneobio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:partnership |
collaborated with various pharmaceutical companies
|
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:product |
Teneobio's therapeutic candidates
|
| gptkbp:products |
Teneobio's proprietary T-cell engagers
|
| gptkbp:research_focus |
gptkb:cancer_treatment
|
| gptkbp:specialization |
antibody engineering
|
| gptkbp:specializes_in |
antibody engineering
|
| gptkbp:technology |
Teneobio's proprietary technology
|
| gptkbp:type |
private company
|
| gptkbp:website |
www.teneobio.com
|
| gptkbp:bfsParent |
gptkb:Amgen
|
| gptkbp:bfsLayer |
4
|